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Long noncoding RNA (lncRNAs)The key information processing units within gene regulatory networks are enhancers. Enhancer activity is
associated with the production of tissue-speciﬁc noncoding RNAs, yet the existence of such transcripts during
cardiac development has not been established. Using an integrated genomic approach, we demonstrate that
fetal cardiac enhancers generate long noncoding RNAs (lncRNAs) during cardiac differentiation and morpho-
genesis. Enhancer expression correlates with the emergence of active enhancer chromatin states, the initiation
of RNA polymerase II at enhancer loci and expression of target genes. Orthologous human sequences are also
transcribed in fetal human hearts and cardiac progenitor cells. Through a systematic bioinformatic analysis,
we identiﬁed and characterized, for the ﬁrst time, a catalog of lncRNAs that are expressed during embryonic
stem cell differentiation into cardiomyocytes and associated with active cardiac enhancer sequences.
RNA-sequencing demonstrates that many of these transcripts are polyadenylated, multi-exonic long noncoding
RNAs. Moreover, knockdown of two enhancer-associated lncRNAs resulted in the speciﬁc downregulation of
their predicted target genes. Interestingly, the reactivation of the fetal gene program, a hallmark of the stress
response in the adult heart, is accompanied by increased expression of fetal cardiac enhancer transcripts. Alto-
gether, these ﬁndings demonstrate that the activity of cardiac enhancers and expression of their target genes
are associated with the production of enhancer-derived lncRNAs.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
The development of the heart and tissue remodeling that occurs in
the adult heart during the response to damage are complex biological
processes modulated by the coordinated spatiotemporal execution
of cardiac gene regulatory networks (GRNs) [1]. Cardiac GRNs are hard-
wired by groups of evolutionarily conserved cardiac transcription
factors (TF) including NKX2.5, MEF2c, SRF and GATA4 [2], whichgulatory networks; CPC, cardiac
y; RNAP2, RNA polymerase II.
rdiology Unit, Department of
11 Lausanne, Switzerland. Tel.:
, thierry.pedrazzini@chuv.ch
. This is an open access article underinteract with target cis-acting regulatory modules to drive appropriate
downstream gene expression. The functional interconnections between
upstream signaling pathways, cardiac TFs and their target genes direct
cell speciﬁcation anddifferentiation, andultimately cardiacmorphogenesis.
Moreover, cardiac GRNs are exquisitely sensitive to genetic and environ-
mental signals, with perturbations of these networks being responsible
for the full spectrumof inherited and acquired cardiac diseases. Compensa-
tory maladaptive mechanisms, which take place in the damaged heart, re-
sult in an increase in cardiomyocyte size and ﬁbroblast proliferation,
leading to cardiac hypertrophy and ﬁbrosis. Importantly, hypertrophied
cardiomyocytes are characterized by expression of a gene program remi-
niscent of that activated during embryonic development [1,3].
Although combinatorial TF binding at proximal promoters is impor-
tant and has been relatively well characterized [2], the key information
processing units and regulators of gene expression within the cardiac
GRN are enhancers [4,5]. Enhancers are an enigmatic class of regulatory
modules, which lie far from the transcriptional start sites of their targetthe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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environmental cues to specify and dictate GRN activity [4,6]. Enhancer
function is thought to involve direct and indirect promotion of tran-
scription at target gene promoters. Through direct interaction with the
basal transcriptional machinery and indirect remodeling of the local
chromatin environment at target promoters, enhancers potentiate tran-
scriptional initiation and elongation [4]. There is also strong evidence to
suggest that enhancer function requires chromatin looping to bring
regulatory factors into direct physical contact with their target pro-
moters. However, the biochemical mechanisms by which this might
selectively occur are poorly characterized. Recent studies have shed
light on this selectivity problem, demonstrating that active enhancers
generate noncodingRNAs (ncRNAs), and that these transcripts are func-
tionally required for enhancer activity [5,7–12]. Importantly, enhancer-
associated ncRNAs are dynamically expressed in response to various
stimuli including chemical, hormonal, electrophysiological, p53-
dependant, and differentiation inducing signals. These dynamic expres-
sion proﬁles correlated with both enhancer activity and downstream
target gene expression [8–11,13]. Importantly, enhancer-derived
ncRNAs play fundamental roles in targeting chromatin remodeling
complexes to the appropriate gene promoters [11,13–16], and thereby
facilitate the formation of chromatin loops [12,13,17,18].
Enhancer-associated ncRNAs have been characterized in a limited
number of cell types and contexts but evidence for function in complex
developmental and pathological responses, particularly cardiogenesis
and maladaptive myocardial remodeling, is lacking. Recently, the utili-
zation of high-throughput epigenomic screens has made possible the
identiﬁcation of hundreds of bona ﬁde fetal cardiac enhancers in both
human and mouse [5,19–21]. Here, we provide evidence that some of
these fetal cardiac enhancers are transcribed, generating ncRNAs during
cardiogenesis both in vivo and in vitro. Global transcriptomic proﬁling
reveals that hundreds of enhancers generate novel multi-exonic and
polyadenylated long noncoding RNAs (lncRNAs). Interestingly, ncRNA
expression correlates with that of their predicted downstream target
genes. Identiﬁed transcripts are speciﬁcally enriched and differentially
expressed in mouse and human cardiac progenitor cells. To highlight
the functional importance of selected transcripts, we demonstrate that
target genemodulation is possible via knockdown of a speciﬁc enhancer
associated lncRNA. Finally, the maladaptive reactivation of the ‘fetal-
gene’ program post myocardial injury is also accompanied by the re-
expression of fetal enhancer-associated transcripts. The demonstration
that cardiac enhancers generate functional cardiac enriched transcripts
will have wide ranging consequences for our understanding of cardiac
GRNs controlling cardiac development and disease.
2. Methods
For full details, see online supplement.
2.1. ChIP sequencing from mouse and human embryonic and adult tissues
For ChIP-Seq analysis of human andmouse fetal and adult hearts we
utilized previously published data sets [19,20]. Data can be found and
analyzed on the GEO website (GEO accession numbers GSE32587 and
GSE22549).
2.2. Transgenic mouse enhancer assay
Mouse transgenic enhancer assays were previously executed and
described [19,20].
2.3. Flow cytometry
Mouse ES cells and EBs were dissociated using FACS medium and
ﬁltered through a 40-μm cell strainer. Live cells were gated on the
basis of side scatter, forward scatter and propidium iodide exclusion.Flow cytometry gates were set using control wild type ES cells not con-
taining the Nkx2.5–EmGFP cassette. Plates were analyzed for EmGFP ex-
pression using the BD FACScan (BD Biosciences). Nkx2.5–EmGFP
positive cells were sorted from EBs using BDFACS Aria I (BD
Biosciences).
2.4. Mice
For enhancer derivedRNAandmarker/target gene expression proﬁl-
ing in embryonic and adult mouse hearts' post-cardiac injury, C57BL/6J
and CD-1 background mice were used. Animal experiments were ap-
proved by the Government Veterinary Ofﬁce (Lausanne, Switzerland)
and performed according to the University of Lausanne Medical School
institutional guidelines.
2.5. Cardiac injury models — microsurgery
Transverse aortic constriction — Chronic pressure overload was
induced in 12-week old mice by transverse aortic constriction (TAC).
Ligation of the left anterior descending artery—Myocardial infarction
in mice was induced as previously described. See extended experimen-
tal procedures.
2.6. Echocardiography
Transthoracic echocardiographies were performed using a 30-MHz
probe and the Vevo 770 Ultrasound machine (VisualSonics, Toronto,
ON, Canada).
2.7. Embryonic stem cell culture and differentiation
Nkx2.5–EmGFP BAC reporter ES cell line (129/OlaHsd strain, subline
E14Tg2A.4) was kindly provided by Edward C Hsiao (Gladstone Insti-
tute of Cardiovascular Research, San Francisco) and maintained and
cultured as previously described [22]. Cells were cultured on mouse
embryonic ﬁbroblast feeders or on gelatinized plates in standard ES
cell medium supplemented with 1000 U/ml of LIF. Cardiac differentia-
tion of ES cells was induced by aggregating aliquots containing 1000
cells in hanging drops to form embryoid bodies [23].
2.8. Primary cell cultures
Human fetal heart chambers and cardiac progenitor cells were
isolated as previously described [24].
2.9. RNA isolation, reverse transcription, end-point PCR and quantitative
PCR
RNA was isolated using the RNeasy Kit (Qiagen) according to the
manufacturer's instructions, using on columnDNase treatment. Compli-
mentary DNA was generated using the SuperScript III kit (Invitrogen)
with random hexamer primers. qRT-PCR was carried out using the
Applied Biosystems SYBR Green PCR kit and an ABI Prism 7500 cycler
and analyzed using the ΔΔCt method.
2.10. Cell culture and transfection
P19CL6 cells (RCB2318, RIKEN Cell Bank, Japan) were cultured in
DMEM with 10% FCS and antibiotics. Transfection of P19CL6 cells with
pLKO.1-puro-UbC-Tag635™ (containing shRNAi, Sigma Aldrich) was
performed with Lipofectamine 2000 (Invitrogen) according to the
manufacturer's instructions. EomesER P19CL6 was a kind gift of Dr.
Elizabeth Robertson, University of Oxford, UK. To induce differentiation
in EomesER P19CL6, 1 μg/ml tamoxifen was added to the cell culture
medium for 3 days.
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Total RNA was isolated from adult mouse hearts and differentiating
mouse ESCs using the RNeasy isolation kit (Qiagen). Sequencing librar-
ies were prepared according to the Illumina RNA Seq library kit instruc-
tionswith Poly(A) selection. Librarieswere sequencedwith the Illumina
HiSeq2000 (2 × 100 bp). Paired end RNAseq reads were mapped to
mouse genome build mm9 using TopHat v2.0.5 essentially according
to the protocols outlined in [25]. Using the mapped reads, transcript
models were constructed using Cufﬂinks v2.0.2 for each individual se-
quencing library, masking genes from the UCSC gene set. The resulting
Cufﬂinks models were merged using Cuffmerge, along with the UCSC
gene set to create themain transcript annotation (Gene Expression Om-
nibus (GEO) accession number: GSE60097).
2.12. Encode consortium histone modiﬁcation and RNA sequencing data
For tissue speciﬁc histonemodiﬁcations and RNA-Seq data, we used
the ENCODE associated histonemark and RNA-Seq data sets (tracks are
publicly available on the UCSC browser). For histone marks in differen-
tiationmouse ES cells, we used custom tracks kindly provided by Benoit
Bruneau (UCSF) https://b2b.hci.utah.edu/gnomex/gnomexFlex.jsp [5].
2.13. Statistical analysis
Data throughout the paper are expressed as mean ± SEM. One way
ANOVA was used to test signiﬁcance of data comparisons between ex-
perimental groups, with p values b 0.05 were considered signiﬁcant.
3. Results
3.1. Fetal cardiac enhancers are dynamically expressed during cardiac
morphogenesis
To determine whether cardiac enhancers generated ncRNAs, we
took advantage of a genome-wide epigenomic screen that identiﬁed
3000 mouse fetal cardiac enhancers in the embryonic day (E) 11.5
hearts based on cardiac speciﬁc enrichment of the co-factor p300
(Fig. 1A). Of the 3000 enhancers, approximately 130 were tested
in vivo for β-galactosidase reporter activity, conﬁrming that enhancer
activity drives expression in the heart [20]. Eleven enhancers, named
Mus musculus (mm)67; mm73; mm76; mm77; mm85; mm103;
mm104; mm130; mm132; mm172 and mm256 were then selected
based on several relevant criteria. The main criteria used for the selec-
tion were the proximity of these enhancers to key protein coding
genes involved in cardiac biology, the cardiac-speciﬁc activity of en-
hancers when tested in a reporter transgenic assay, and ﬁnally whether
enhancers confer subregion speciﬁcitywithin theheart. Therefore, six of
these enhancers were proximal to genes encoding cardiac regulatory
proteins such as Myocardin, Myosin light chain-2v, Tbx20 and
Endothelin-1 (Edn1; Supplemental Fig. 1). Most importantly, these en-
hancers drove robust cardiac-speciﬁc activity in mouse embryos
(Fig. 1A). Embryo images obtained with each construct are available
using the enhancer ID at the Vista Enhancer Browser (http://enhancer.
lbl.gov/; [19,20]). Finally, the selected enhancers also exhibited subre-
gion speciﬁcity (Fig. 1A). For example, mm67 exhibited activity only
within the ventricles (LV and RV) and outﬂow tract (OFT), and not in
adjacent atria (RA and LA), as visualized by β-galactosidase activity in
sections of representative embryos. Primers for RT-PCR were then de-
signed in the enhancers as demarcated by the p300 peak to generate
products of at least 100 nucleotides. RT-PCR of enhancer sequences
using total RNA isolated from E11.5 mouse heart, forebrain and limbs
demonstrated the presence of enhancer-associated ncRNAs speciﬁcally
within the heart (Supplemental Fig. 1B). Importantly, expression did
not appear to be a general feature of all active cardiac enhancers since
additional enhancers (mm73, mm76, mm103 and mm256) were notable to produce a transcript in cardiac precursor cells (Supplemental
Fig. 1C).
To determinewhether enhancer-derived transcripts were produced
in a developmentally regulated manner, we proceeded via quantitative
(q)RT-PCR to measure enhancer expression in the whole heart during
development from E9.5 to post-natal day 10 (P10). This developmental
period encapsulates all the major morphogenetic and cell fate deter-
mining events, including cardiac chamber speciﬁcation (E9), matura-
tion (E10 to E18), septation (E11–E18), terminal differentiation and
myocyte exit from cell cycle (P10) [2]. Expression proﬁling demonstrat-
ed that cardiac differentiation andmaturationmarkers, Myh7 andMS1/
STARSwere upregulated as expected during cardiac development (Sup-
plemental Fig. 1D) [26,27]. All selected ncRNAs were dynamically
expressed during development of the heart (Fig. 1B). Enhancer expres-
sion coincided with different cardiac morphogenetic processes occur-
ring at speciﬁc developmental stages. For example, mm77 and mm130
expression is associated with cardiac maturation and septation respec-
tively. Putative cardiac target genes were also dynamically expressed
with expression kinetics correlating with enhancer-associated ncRNAs
(Fig. 1B). The induction of the ncRNAs typically is coupled to expression
of target genes. In some cases, enhancer expression appeared to be re-
pressed once target gene reached maximal levels (see for instance
mm67, -85, -130). Overall, these data demonstrated that enhancer-
associated ncRNAswere dynamically expressed during cardiac develop-
ment coinciding with both target genes and cardiac morphogenetic
processes.
3.2. Enhancer-derived transcripts are enriched in cardiac progenitor cells
To evaluate enhancer expression during cardiogenesis, mouse em-
bryonic stem (ES) cells were induced to differentiate using the hanging
drop model [28] (Figs. 2A and B; Supplemental Fig. 2A). This model
recapitulates embryonic cardiac development in vitro, generating
all appropriate cardiac lineages (Supplemental Fig. 2B). We ﬁrst ex-
amined the temporal gene expression patterns associated with
pluripotency, cardiac mesoderm, cardiac progenitors and differentiated
cardiomyocytes (Fig. 2A). Upon differentiation, the pluripotency
markers Oct-3/4 and Nanog were rapidly downregulated. This down-
regulation occurred concomitantly with expression of Brachyury,
Eomes and Mesp1. The three core cardiac transcription factors Nkx2.5,
Mef2C and GATA4, which specify cardiac progenitors and drive the car-
diac gene program, were signiﬁcantly upregulated by days 3 to 6. This
was followed by robust expression of the cardiac differentiation and
structural proteins, Myh6 and Myh7. Six fetal enhancers were
expressed in differentiating embryoid bodies (EBs), and demonstrated
dynamic expression proﬁles correlating with cardiac differentiation.
Enhancer ncRNAswere predominantly induced at day 6, corresponding
to CPC stage and is associated with putative target gene expression
(Fig. 2B). To conﬁrm that enhancerswere transcribed in cardiac progen-
itor cells, we took advantage of the EmGFP–Nkx2.5 ES cell line [22],
which expresses EmGFP under the control of the endogenous Nkx2.5
promoter, allowing the puriﬁcation of cardiac progenitor cells by
ﬂuorescence-activated cell sorting (FACS) (Figs. 3A and B). EmGFP–
Nkx2.5 ES cells were differentiated and Nkx2.5 expressing cells were
isolated at days 6 and 10 (Fig. 3B). As expected, Nkx2.5 expression
and Myh6 expression were enriched in EmGFP–Nkx2.5 expressing
cells (Fig. 3C). In addition, enhancer-derived transcripts and their asso-
ciated cardiac geneswere also signiﬁcantly enriched in EmGFP–Nkx2.5-
positive CPCs (Fig. 3C).
To precisely determine stage-speciﬁc activation of our cardiac en-
hancers, we took advantage of publicly available chromatin state maps
generated using chromatin immunoprecipitation followed by sequenc-
ing (ChIP-Seq) in differentiating ES cells [5]. Analyses have been execut-
ed in pluripotent mouse ES cells (mES, i.e. Oct4-positive cells), at the
cardiac mesoderm stage (MES, i.e.Mesp1-positive cells), at the cardiac
progenitor stage (CPC, i.e. Nkx2.5-positive cells and GATA-4-positive
A mm67 mm77 mm85 mm104 mm130 mm132 mm172
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cells), corresponding to d0, d3, d3–6 and d6–12 in the hanging drop
differentiation protocol (Supplemental Fig. 2B). Assessment of
H3K27me3 and H3K4me3 (associated with inactive and active canoni-
cal promoters respectively), and H3K4me1 and H3K27ac (associated
with poised and active enhancers) allowed us to analyze chromatin
state transitions at the transcribed fetal enhancers during cardiogenic
differentiation (Supplemental Figs. 3A–D). All enhancers were induced
at the CPC stage, corresponding with enhancer transition from a poised
(H3K4me1) to an active state (H3K4me1, H3K27ac). None of the
expressed enhancers were associated with canonical active promoter
states (H3K4me3), conﬁrming that they represent distal regulatory
elements and not previously unannotated promoters. Importantly
enhancer-associated expression was coupled with enrichment of
initiating RNA polymerase II (RNAP2; phosphorylated at serine 5),
supporting the notion that active enhancers undergo transcription. In
addition, we analyzed the presence of activating marks, i.e. H3K4me3
and initiating RNAP2, at the promoter of Endothelin 1, the predicted
target gene of mm132 (Fig. 2C). Interestingly, enhancer activation and
transcription appeared to precede induction of its target gene.
The enrichment of enhancer-derived transcripts speciﬁcally in cardi-
ac progenitor cells led us to postulate that these enhancers were under
the control of cardiac-speciﬁc transcription factors. We therefore exe-
cuted a pair-wise sequence comparison between mouse and human
sequences to identify evolutionary conserved transcription factor bind-
ing sites (TFBS). All fetal enhancers were enriched with conserved
cardiac TFBS, including GATA4, Nkx2.5, Mef2 and SRF motifs (Supple-
mental Fig. 4). Two enhancers, mm130 and mm172, also contained
additional T-Box motifs, which can be bound by the key cardiac
mesoderm-specifying transcription factor Eomesodermin (Eomes). To
evaluate whether these enhancers were sensitive to activation by
transcription factors, we took advantage of P19CL6 mouse embryonic
carcinoma cells [29], containing an Eomes gene fused to sequences
encoding a mutated estrogen receptor binding domain (EomesER) for
tamoxifen-induced nuclear translocation [30]. Upon tamoxifen activa-
tion, Eomes induces Mesp1 and Lhx1 expression and initiates a cardio-
genic gene program in P19CL6 cells (Supplemental Fig. 4A). In
addition, mm130, mm172 and their putative target genes Tbx20 and
Ednra were transcriptionally induced in the presence of tamoxifen,
suggesting that these enhancers are downstream of an Eomes-
dependant transcriptional axis (Supplemental Fig. 4B). Conversely,
none of the other cardiac enhancers, not containing T-Box motifs,
were induced in the presence of tamoxifen (Supplemental Fig. 4D).3.3. Orthologous human enhancers are transcribed and functional
Multispecies vertebrate and mouse conservation plots suggested
that four of the seven fetal cardiac enhancers (mm67, -85, -130 and
-132) appeared to be evolutionarily conserved in humans (Supplemen-
tal Fig. 5A). We therefore utilized a previously executed genome-wide
ChIP-Seq screen [19], and determined the occupancy proﬁles of
enhancer-associated co-activator proteins at orthologous human
enhancers in fetal and adult human hearts. We observed a signiﬁcant
enrichment of p300/CBP at human orthologs of mm67, -85 and -130
speciﬁcally within the fetal heart indicating that these enhancers were
active during development (Fig. 4A). To demonstrate regulatory conser-
vation of orthologous human enhancers, the human mm130 sequence
was isolated and tested in a mouse transgenic enhancer assay. TheFig. 1. Fetal cardiac enhancers are expressed in the developing heart. A. ChIP-Seq proﬁles of
forebrain (dark blue), midbrain (light blue) and limb (green). Vertebrate conservation plots (b
enhancer region. Numbers at the right indicate overlapping extended reads. Below boxes are La
was extracted from embryonic (E9.5–E18.5) and neonatal (P1–P10) mouse hearts and sub
transcripts: mm67, mm85, mm77, mm104, mm130, mm132 andmm172, and their putative ta
sion in the E11.5 heart. Mean ± SEM; n = 6–8. * indicates statistical signiﬁcance, p b 0.05.orthologous human sequence recapitulated the enhancer activity of
themouse sequence, demonstrating that human orthologous enhancers
were functionally conserved (Fig. 4B). In order to conﬁrm that human
orthologous enhancers were expressed, RT-PCR was carried out on
total RNA extracted from human fetal ventricles and atria as well as
from human Nkx2.5-positive CPCs isolated at gestational week 12
(Fig. 4B; Supplemental Fig. 5B) [24]. Primers for RT-PCR were designed
in regions contained within the enhancer as demarcated by the p300/
CBP peak in order to generate products of at least 100 nucleotides.
Transcripts for conserved human enhancers were present in atria,
ventricles and isolated CPCs (Fig. 4B).
Considering the enrichment of enhancer-associated transcripts in
mouse ES cell-derived CPCs, we proceeded to determine the expression
of human orthologs of mm67, -85 and -130 in differentiating human
CPCs [24] (Supplemental Fig. 5B). CPC differentiation was accompanied
by a robust induction in the cardiac regulatory transcription factors
Mesp1 and the cardiac structural protein Myh6 at 7 and 14 days fol-
lowing induction (Fig. 4C). Consistently, human enhancer transcripts
were signiﬁcantly upregulated at day 7 (mm67) or day 14 (mm85
and -130) of cardiac differentiation (Figs. 4D, E). This activation is
also associated with signiﬁcant upregulation of Myocardin. There-
fore, human orthologous enhancer-derived ncRNAs appeared to be
functionally conserved during differentiation of isolated cardiac
progenitors.3.4. Global discovery of enhancer-associated lncRNAs during cardiac
differentiation
Enhancer-associated ncRNAs are currently known to exist in several
forms: a) bidirectional, unspliced, non-polyadenylated eRNAs [9];
b) unidirectional, intergenic, spliced and polyadenylated long
noncoding RNAs with a canonical promoter chromatin signature
(H3K4me3) [10]; and c) unidirectional, intra- and intergenic, spliced
and polyadenylated multi-exonic long noncoding RNAs with
enhancer-associated chromatin signatures (H3K4me1 and H3K27Ac)
[11,31]. Since reverse transcription reactionswere primedwith random
hexamers in initial experiments, wewere not able to readily discern the
nature of our enhancer-derived ncRNAs. To address this issue, we
assessed transcription of the Poly(A)+ fraction of the transcriptome
using high-throughput sequencing (RNA-Seq). Total RNA was isolated
from differentiating ESCs at day 0 and day 6 of cardiac differentiation,
corresponding to pluripotent (d0) and cardiac precursor cells (CPCs,
d6) (Supplemental Figs. 2A and B). These temporal pointswere selected
to allow the identiﬁcation of ncRNAs being transcribed from develop-
mental cardiac enhancers during cardiac differentiation. Furthermore,
day 6 of ESC differentiation corresponds approximately to E11.5 in the
developing heart, the temporal point at which our fetal enhancers
were identiﬁed. Furthermore, enhancer-derived transcripts were
maximally expressed at day 6 during ESC cardiac differentiation (Fig. 2).
We also integrated ChIP-Seq data generated in a comparable direct-
ed differentiation system that recapitulated the step-wise differentia-
tion of mESCs (ES) to cardiac precursor cells (CPCs) (Supplemental
Fig. 2) [5]. This facilitates the annotation of chromatin states at
underlying genomic sequence and assigns ncRNAs as either promoter-
(plncRNA, H3K4me3) or enhancer-associated (elncRNA, H3K4me1/
H3K27Ac) lncRNAs. Furthermore, this allows us to identify enhancers
that are activated during cardiac differentiation (i.e. between d0 and
d6), and couple activation with differential expression of associatedp300 occupancy at cardiac enhancers. Coverage by extended p300 reads in heart (red),
lack) were obtained from the UCSC genome browser. Gray boxes correspond to candidate
cZ-stained embryos and isolated hearts with in vivo enhancer activity at E11.5. B. Total RNA
jected to reverse transcription followed by quantitative RT-PCR. Enhancer-associated
rget genes: Myocardin, Myosin light chain 2 and Tbx20. Results are normalized for expres-
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selected RNA and, using TopHat [25], we mapped a total of N2 billion
RNA-Seq reads to the mouse genome (Supplemental Fig. 6A). Tran-
scripts were reconstructed de novo from these data using Cufﬂinks
[25], and compared with UCSC gene annotations. To identify lncRNAs
with high conﬁdence, we considered only multi-exonic transcripts
greater than 200 nucleotides in size, and discarded any that overlap
with known mRNA exons on the same strand or that have predicted
coding potential (Supplemental Fig. 6; Coding potential score b4,
Fig. 5C). This analysis reconstructed 18,521 multi-exonic transcripts, of
which 14,376 (3222 upregulated and 2881 downregulated comparing
undifferentiated vs. differentiated ESCs) correspond toUniversity of Cal-
ifornia Santa Cruz (UCSC) annotated protein coding genes (Figs. 5A, D,
Supplemental Tables 3, 4). Our lncRNA annotation pipeline identiﬁed
4145 multi-exonic lncRNAs. There were 1537 (244 upregulated and
297 downregulated) UCSC annotated lncRNAs and 2608 (311 upregu-
lated and 806 downregulated) novel previously unannotated lncRNAs.
Novel lncRNAs and UCSC lncRNAs were expressed at signiﬁcantly
lower levels than coding genes (Fig. 5B). Furthermore, to verify the non-
coding nature of our novel lncRNA candidates, we calculated the Gene
ID coding potential score for each transcript and found that these
novel transcripts have minimal protein-coding potential, comparable
to UCSC annotated lncRNAs (Fig. 5C).
To classify our identiﬁed novel and annotated lncRNAs, we
examined their overlap with speciﬁc chromatin states characterized in
differentiating ESCs at the pluripotency (ES), mesodermal (MES) and
cardiac precursor (CPC) stages of cardiac differentiation [5]. LncRNAs
were classiﬁed as being associated with either a canonical promoter
(plncRNA, H3K4me3) or an active enhancer (elncRNA, H3K4me1/
H3K27Ac). Interestingly, novel lncRNAs were more associated with
active enhancers (57% elncRNAs) when compared to previously
annotated UCSC lncRNAs (34% elncRNAs) (Fig. 5E). These ﬁndings
demonstrate that globally enhancers active during development are
commonly associated with the production of Poly(A)+ multiexonic
lncRNAs, supporting the notion that enhancer-associated transcription
is a common feature of cardiac developmental enhancers. Recent
studies have demonstrated that elncRNAs and plncRNAs exhibit signif-
icant differences in transcript abundance with plncRNAs typically
more highly expressed [31]. We also ﬁnd that plncRNAs are more
expressed in differentiating ESCs (p = 0.003 vs. elncRNA) than
elncRNAs (Fig. 5F).
We then determined if cardiac enhancers identiﬁed in E11.5 fetal
hearts were associated with novel multi-exonic Poly(A)+ lncRNAs in
ES cells. We identiﬁed one enhancer, mm85 that was associated with
a novel lncRNA (Fig. 5G), while other enhancers were not. Considering
that these enhancers generate a transcript, we suggest that they are
likely to encompass the bidirectional non-polyadenylated eRNA class
[9]. Since enhancer-associated transcription correlates with enhancer
activity, we therefore proceeded to visualize chromatin state transitions
occurring at all lncRNAs identiﬁed in this systematic analysis (Fig. 5H). A
signiﬁcant fraction of lncRNAs with active enhancer states exhibit
exquisite stage speciﬁc chromatin state transitionsduring cardiac differ-
entiation. This ﬁnding further supports the notion that cardiac develop-
mental enhancer activity is correlated with the expression of associated
ncRNAs. Finally, we ﬁnd that expression of a signiﬁcant proportion of
elncRNA correlates with the expression of their proximal coding
genes, in agreement with previous studies (Supplemental Table 5)
[31]. These ﬁndings support the notion that enhancer-associated
lncRNAs regulate the expression of target protein coding genes in cis
during the cardiac differentiation process. To summarize, our integrated
genomic analysis of differentiating ESCs has identiﬁed hundreds of
lncRNAs associated with cardiac developmental enhancers. TheseFig. 2. Fetal cardiac enhancers are expressed during embryonic stem cell differentiation into the
tion. A. Relative RNA levels of stage-speciﬁc markers of cardiac differentiation. B. Relative RNA
ation. C. UCSC genome browser views of ChIP-Seq data at the mm132 and Edn1 loci for mES, Menhancer-associated lncRNAs are differentially expressed in a coordi-
nated manner with enhancer state transitions and correlate in expres-
sion with putative target genes.3.5. Fetal enhancers are active and transcribed in the adult heart
Pathological cardiac remodeling is accompanied by the reactivation
of a fetal gene program in the adult heart. Therefore, we determined
whether this reactivation manifested at the level of fetal enhancer
expression. Utilizing ENCODE ChIP-Seq data [32,33], we ﬁrst demon-
strated that four of the mouse fetal enhancers (mm67, -85, -130 and
-132) were associated in the adult mouse heart with epigenetic marks
identifying active chromatin, i.e. enrichment with p300, H3K4me1 and
H3K27ac (Supplemental Fig. 7A). We also observed heart-speciﬁc
occupancy by the transcriptional machinery (RNAP2 and DNaseI hyper-
sensitivity) at all four fetal enhancers. These enhancer signatures were
only present in the heart and not in the liver (Supplemental Fig. 7A)
or other tissues (not shown), conﬁrming the cardiac-speciﬁc nature of
these regulatory sequences. To conﬁrm that these epigenetically active
enhancers were expressed, total RNA was isolated from the adult
mouse heart and liver. RT-PCR analysis conﬁrmed that these four
enhancer produced ncRNA in the adult heart (Fig. 6A). In contrast,
mm104 and mm172 were not expressed. Furthermore, mm77 was
excluded of the analysis due the possible confounding expression of
Myl2within themm77 locus.We then determined enhancer expression
in two patho-physiological models of cardiac injury. We ﬁrst used a
myocardial infarctionmodel obtained by left anterior descending artery
(LAD) ligation (Figs. 6A and B; Supplemental Fig. 7B). Fourteen days
post-infarction, the myocardium was characterized by remodeling, i.e.
increased heartweight (HW) to bodyweight (BW) ratio, left ventricular
(LV) mass, and septal and LV wall thickness as well as decreased
ejection fraction (EF) as assessed by echocardiography (Fig. 6B; Supple-
mental Table 2). Total RNAwas isolated from the border zone of infarct-
ed region and corresponding region in sham-operatedmice. Expression
proﬁling via qRT-PCR analysis demonstrated a robust reactivation of the
fetal gene program (Fig. 6C) including upregulation of cardiac markers
of stress (ANP, BNP, βMHC) and pro-ﬁbrotic genes (Col1, Tgfb1). Of
the expressed enhancers in the adult heart, mm130 and -132 were
signiﬁcantly upregulated post-infarction (Fig. 6C). This induction
correlated positively with the upregulation of their target genes Tbx20
and endothelin-1. Interestingly, both Tbx20 and endothelin-1 have
been implicated in pathological cardiac remodeling post myocardial
injury [34,35]. In contrast,mm67 and -85, aswell as their putative target
gene Myocardin were not signiﬁcantly regulated post injury (Fig. 6C).
To evaluate whether enhancers demonstrated active transcription
during the acute phase of the response to infarction, we measured
expression of all enhancers on days 1 and 7 (Supplemental Fig. 8).
Enhancers were minimally activated at these early time points. Signiﬁ-
cant induction ofmm132 and its target gene Edn1was nevertheless ob-
served (Supplemental Fig. 8). Furthermore, mm85, -67 and their
predicted target gene, Myocardin, were all signiﬁcantly downregulated
7 days post infarction (Supplemental Fig. 8).
In a second series of experiments, we used a model of cardiac
pressure overload obtained by transaortic constriction (TAC; Supple-
mental Fig. 7C). Seven days after surgery, the myocardium exhibited
cardiac hypertrophy and reactivation of the fetal gene program
(Fig. 6D). Again, pressure overload-induced activation of fetal gene
expression was associated with induction of mm132 and its target
gene endothelin-1. Endothelin-1 is incidentally one of the best charac-
terized hypertrophic agonists post cardiac injury, responding to numer-
ous cardiac stresses and modulating the maladaptive pathologicalcardiogenic lineage. RNAwas isolated on d0, d3, d6, d9 and d12 of embryoid body forma-
levels of enhancer-associated ncRNAs and putative target genes during cardiac differenti-
ES, CPC and CM representing different stages of cardiac differentiation.
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were even downregulated after TAC.
To determine the transcript structure and nature of the fetal
enhancer-derived ncRNAs expressed in the adult heart, we utilized a
recently published adult heart-speciﬁc lncRNA data set [36]. This
study executed 100 bp paired-end RNA-sequencing of Poly(A)+ RNA
in the heart of 8 week-old C57BL/6 mice followed by de novo lncRNA
identiﬁcation and characterization. Utilizing this data, we found that
in the adult mouse heart, two enhancers, mm85 and mm77, wereassociated with unidirectional Poly(A)+ multi-exonic lncRNAs
(Fig. 7A; Supplemental Figs. 9A–E). These ncRNAs exist as multiple iso-
forms and are derived from the plus (mm77) and minus (mm85)
strands. These data suggest that the other expressed enhancers were
likely generating non-polyadenylated enhancer-derived ncRNAs. Delin-
eating the intragenic structure of the multi-exonic ncRNAs associated
with mm67 and mm132 was difﬁcult to assess as our analysis is com-
promised by the presence of the parent coding gene transcripts (Sup-
plemental Fig. 9C). Altogether, these results demonstrate that fetal
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63S. Ounzain et al. / Journal of Molecular and Cellular Cardiology 76 (2014) 55–70cardiac enhancers are differentially expressed in the adult heart post
injury, potentially contributing to the global reactivation of the fetal
gene program.
3.6. Fetal enhancer-associated noncoding RNAs are functional
To assess the functional importance of enhancer-associated ncRNAs,
we designed small interfering RNAs (shRNAi) to target the mm85derived lncRNA (Figs. 7A and B). Knockdown experiments were
performed in P19CL6 mouse embryonic carcinoma cells. Transfection
of P19CL6 cellswith shMM85-1 and shMM85-2, but not control shRNAi,
reduced the enhancer transcript by approximately 80% (Fig. 7C). The
predicted target gene of mm85, Myocardin, was also signiﬁcantly
downregulated (Fig. 7C), demonstrating that mm85 enhancer derived
lncRNA was required for Myocardin expression. Since many protein-
coding genes are known to be regulated by multiple enhancers, we
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64 S. Ounzain et al. / Journal of Molecular and Cellular Cardiology 76 (2014) 55–70also characterized the mm67 enhancer, which is located within the
Myocardin gene (Fig. 7B). Upon mm85 ncRNA knockdown, the mm67
ncRNA was upregulated approximately two fold (Fig. 7C). Importantly,
the more proximal protein coding gene, Map2k4, which is not apredicted target of mm85 based on its poor cardiac speciﬁcity, was
not affected by mm85 ncRNA knockdown. Considering that the
mm85-associated lncRNA is also expressed in the adult heart and mod-
ulated concomitantlywithmyocardin 7 days post infarction,wewanted
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65S. Ounzain et al. / Journal of Molecular and Cellular Cardiology 76 (2014) 55–70to conﬁrm that themm85 lncRNA regulatedmyocardin in differentiated
cardiomyocytes (CMs). As an experimental model, we used isolated
neonatal mouse CMs. Cells were transfected with modiﬁed antisense
oligonucleotides (GapmeRs) targeting mm85 (Fig. 7D). The associated
transcript was reduced by greater than 80%. Myocardin was again
signiﬁcantly downregulated in a speciﬁc manner whereas Map2k4remained unaffected. These results indicate that the mm85 enhancer-
associated lncRNA is required for cis-activation of Myocardin and this
regulation occurs with high speciﬁcity.
To further exemplify the functional importance of fetal enhancer-
derived lncRNAs in the adult heart, we selected a novel lncRNA identi-
ﬁed in the RNA-Seq analysis of differentiating embryonic stem cells.
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well expressed in a number of differentiated adult tissues, including
the heart (Fig. 8A). In preliminary experiments, we determined further-
more that this particular lncRNA was highly expressed in cardiac ﬁbro-
blasts. Therefore, we used isolated neonatal mouse cardiac ﬁbroblasts,
whichwere transfectedwithGapmeR targeting the last exon of this par-
ticular lncRNA (Fig. 8B). Signiﬁcant knockdown of the lncRNA (N50%,
*p b 0.05) resulted in a signiﬁcant decrease in the predicted targetgene, Smad7 (N30%, *p b 0.05) (Fig. 8C). These data further support a re-
quirement of enhancer-derived lncRNAs for the expression of proximal
target genes in cardiac ﬁbroblasts.
4. Discussion
Enhancers are the key information processing units within the
cardiac GRN. Identiﬁcation and characterization of cardiac enhancers
68 S. Ounzain et al. / Journal of Molecular and Cellular Cardiology 76 (2014) 55–70are therefore essential to decipher the molecular basis of cardiogenesis
and pathological remodeling [37]. A number of important recent studies
have attempted to address this issue, utilizing genome-wide
epigenomic screens to identify fetal and adult cardiac enhancers [19,
20,37,38]. Despite this progress, a physiologically relevant annotation
and analysis is still lacking. Considering the recent identiﬁcation of a
novel class of enhancer-associated regulatory ncRNAs that are essential
for enhancer function [8–10,12,13,18], we set out to determinewhether
cardiac enhancers are transcribed and generate cardiac-speciﬁc ncRNAs.
Here,we provideﬁrst evidence that bona ﬁde fetal cardiac enhancers are
transcribed dynamically during cardiac development and disease. This
highly regulated expression, both in vivo and in vitro, is consistent
with expression kinetics of enhancer associatedncRNAs in other cellular
systems [8]. It also supports the notion for these transcripts being
functionally important rather than artifacts or transcriptional noise.
Fetal enhancer ncRNAs are expressed in a cell and tissue speciﬁc
manner, correlating with the activity of the enhancer and the expres-
sion of the predicted cardiac enriched target genes [19,20]. Further-
more, we demonstrate that both mouse and human enhancer-
associated ncRNAs are highly enriched in fetal cardiac progenitor cell
populations and that a signiﬁcant fraction of the intergenic multi-
exonic poly(A)+ lncRNAs identiﬁed in these cells are derived from
active developmental enhancers. Importantly, very-deep sequencing
allowed us, to probe the association and presence of such enhancer-
derived transcripts at an unprecedented level in differentiating ESCs.
Importantly, we have included in this analysis only transcripts with no
predicted coding potential based on in silico determination (Gene ID
score b 4). Nevertheless, we cannot formally exclude that some of
these lncRNAs might be translated into small peptides under particular
conditions. This warrants further investigation. Finally, we demonstrate
that the reactivation of the fetal gene program post myocardial stress is
also accompanied by the re-expression of fetal enhancers. Interestingly
our group has recently proﬁled and characterized the long noncoding
transcriptome in the adult mouse heart followingmyocardial infarction
[36]. Notably, the vast majority of novel multi-exonic unidirectional
lncRNAs that were identiﬁed are associated with adult heart-speciﬁc
cardiac enhancers, comparable to our observations here in ESCs differ-
entiating towards the cardiogenic lineage. Furthermore, the differential-
ly modulated fraction of lncRNAs post infarction, was even more
enrichedwith cardiac enhancer states, suggesting that cardiac enhancer
lncRNAs are required for the global transcriptional reprogramming that
underpins maladaptive remodeling and subsequent transition to heart
failure.
Many evolutionary conserved adult cardiac enhancers exhibit
RNAP2 occupancy in the mouse heart. Furthermore, thousands of
recently discovered novel cardiac enhancers identiﬁed in differentiating
mES cells (at cardiac progenitor and cardiomyocyte stage) are associat-
ed with initiating RNAP2 when enhancers are in an active state
(H3K4me1 and H3K27ac), supporting the notion that enhancer-
associated transcription is a common feature of cardiac enhancers.
Previously characterized enhancer ncRNAs have been demonstrated
to compose two functionally and structurally diverse ncRNA classes.
The so-called enhancer-RNA (eRNA) class are unspliced, non-
polyadenylated and bidirectionally transcribed [8,9]. The long non-
coding RNA (lncRNA) class are RNAP2 transcribed, polyadenylated
and multi-exonic [10,11]. To determine which class the enhancer-
associated ncRNAs described in the present study represent, we
executed RNA-Seq on Poly(A)+ RNA derived from differentiating
mouse ESCs and integrated this with publicly available ChIP/RNA-
Seq data sets [5,33]. Ab initio transcript reconstruction identiﬁed
novel, unidirectional, Poly(A)+ and multi-exonic ncRNAs mapping
to mm85 and mm77. Interestingly, both transcripts were associated
with different chromatin states. Mm77 was enriched with
H3K4me3 at its transcription start site, rendering it similar to
intergenic lincRNAs [39] and enhancing lncRNAs [10]. This is also
consistent with mm77 potentially representing an alternative TSSfor the Myl2 gene itself. Mm85 was of particular interest as it was
not associated with H3K4me3 but enriched with a purely active
enhancer-associated chromatin state (H3K4me1 and H3K27ac)
rendering it comparable to the recently described elncRNAs [31].
Extending this conclusion, we demonstrate globally that numerous
developmental enhancers are associated with unidirectional multi-
exonic lncRNAs. The very-deep sequencing approach allowed us to
identify hundreds of previously unannotated novel lncRNAs derived
from these active enhancers. Interestingly, the novel lncRNAs were
more associated with active enhancers as compared to UCSC
lncRNAs, comparable with recent observation in the adult heart [36].
LncRNAs have well characterized roles in gene regulation [15,16,
40–43]. They have been shown to be master cell-speciﬁc cis- and
trans-modulators of gene expression, via direct regulation of target
gene promoter activity or indirect interaction with coding and noncod-
ing regulatory networks [15,41–45]. In particular, lncRNAs are especial-
ly important for regulating the epigenome, which is established as a
major dynamic determinant of cardiac gene expression [5,15,44].
LncRNAs are more cell-speciﬁc in their expression compared to protein
coding mRNAs [46]. They function as molecular scaffolds, targeting
epigenetic and chromatin remodeling complexes to their correct geno-
mic loci [15,44]. Analogous to the enhancer-derived lncRNA HOTTIP
[13] and to activating lncRNAs [12], the cardiac enriched lncRNAs
described herein could potentiate chromatin looping between enhancer
sequences and cardiac-speciﬁc gene promoters. Interestingly, many
lncRNAs have been shown to interact with the Polycomb Repressive
Complex 2 (PRC2), known to regulate histone methylation [47,48].
Two recent studies have implicated this complex in epigenetic
programming in cardiac precursor cells, being critical for cardiac speci-
ﬁcation, development and adultmyocardial adaptation to stress [49,50].
It would be of interest to determinewhat proportion of our newly iden-
tiﬁed enhancer associated lncRNAs are also able to interact with and
target PRC2 in a cardiac developmental speciﬁc manner, akin to the
regulatory roles conferred by the cardiogenic lncRNAs, Braveheart and
Fendrr [51,52].
We also demonstrate that enhancer-associated ncRNA expression is
regulated in pathophysiological models of heart disease in vivo. These
data provide a foundation for the functional annotation of the cardiac-
enriched lncRNA transcriptome and suggests that many of these
noncoding transcripts may encompass the enhancer ncRNA class.
Furthermore, the cardiac enhancers analyzed in this study are highly
speciﬁc to temporal and spatial cues. This is evidenced by their spatial
domains of activity in the developing heart as well as their temporal
activation kinetics during in vitro cardiogenesis and in response to path-
ophysiological stimuli. Since cardiac enhancer ncRNAs exhibit signiﬁ-
cant cell-speciﬁc and context-dependant expression [46], this renders
them ideal candidates for therapeutic approaches in the heart. Indeed,
as demonstrated for mm85 and SMAD7-lncRNA, it is possible to modu-
late target gene expression via enhancer-associated ncRNA manipula-
tion. In this context, quantitative proﬁling of cardiac enhancer-
associated ncRNAs can provide exquisite insights into cardiac enhancer
activity and more globally into the regulatory state of the cardiac GRN
during various cardiogenic processes. Finally, it is important to note
that the existence of functional enhancer-associated ncRNAs radically
alters also the way we conceptualize genetic variations. Indeed, the
vast majority of single nucleotide variants (SNVs) associated with
cardiac pathologies and cardiovascular risks reside in noncoding
sequences [53–56]. It is assumed that SNVs within noncoding regulato-
ry elements impact upon transcription factor binding motifs [57].
However, a number of SNVs were actually found in the human
orthologs of some of the mouse cardiac enhancers characterized in the
present study (data not shown). Our ﬁndings therefore demonstrate
that we should also consider the impact of these noncoding SNVs on
the expression, structure and function of enhancer-derived lncRNAs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yjmcc.2014.08.009.
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